I am a scientist and entrepreneur who has driven human therapeutics from idea...

iconfinder_113_Chemical_dope_lab_science
iconfinder_27_plan_strategic_strategy_ta
iconfinder_70_Agreement_deal_handshake_B

... to Series A

Get It Here

Proof of Concept

Get It Here

Technical Strategy

Get It Here

Business Strategy

Get It Here

Early-stage Operations

Get It Here

Idea

Scientific literature

 

As seen in:

Press

"The potential applications of RCas9 are seemingly boundless."

"Such an approach has the potential to be applied to diverse transcript types in multiple cell systems" 

bioessays.png
celllogo2.png
NRG logo (1).png
nmethlogo (1).png
 

Scientific literature

 

As seen in:

Press

"Researchers [have used] CRISPR to fix problems in RNA rather than to change DNA, a promising step for a group of diseases, including Huntington’s and amyotrophic lateral sclerosis, that have no cure."

celllogo2.png
fierceBTlogo (4.png

Proof of concept

iconfinder_113_Chemical_dope_lab_science
 
 

Technical strategy

Business strategy

Early-stage operations

iconfinder_27_plan_strategic_strategy_ta

Experience

Co-founder and Chief Technology Officer at Locana, Inc.

Awards

STAT Wunderkind: selected during a nationwide search for "the next generation of scientific superstars" 

BIOCOM Catalyst: among 15 awardees to have made unique contributions to the biotech community in Southern California

wunder3.png
bcc4.png
lcoana3.png

Press

"Locana bags $55M for RNA-targeting gene therapies"

"Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA"

fierceBTlogo (4.png
xconomy.png

Series A

iconfinder_70_Agreement_deal_handshake_B
 

Preclinical development

Published preclinical studies

 

As seen in:

 

Co-first author of a series of preclinical studies that establish the safety and efficacy of RNA-targeting Cas9 in a model of the most common type of adult-onset muscular dystrophy.

nbme.png